Jazz Pharmaceuticals Director Bruce C. Cozadd Sells $1.5M in Shares via 10b5-1 Plan
Jazz Pharmaceuticals plc
Subscribe to track JAZZ
Premium users can add ticker alerts and receive realtime notification updates.
Filing Summary
📊 Insider Sale Alert: Jazz Pharmaceuticals plc ($JAZZ) Insider: Bruce C. Cozadd (Director) Action: Sold 6,000 shares at $250.13/share ($1,500,780 total) Plan: Rule 10b5-1 pre-scheduled trading plan Remaining Holdings: 351,875 shares directly owned Additional Transactions: 1,219 shares withheld for tax obligations ($294,281 total value)
Comprehensive Analysis
Insider Transaction Overview
On September 1, 2026, Bruce C. Cozadd, Director at Jazz Pharmaceuticals plc ($JAZZ), executed an open-market sale of 6,000 Ordinary Shares at an average price of $250.13 per share, for aggregate gross proceeds of approximately $1,500,780.
Additionally, on August 31, 2026, two tax withholding transactions (Code F) totaling 1,219 shares were executed at prices of $244.064 and $241.3899 per share to satisfy tax obligations upon the vesting of restricted stock units.
Key Highlights
- Pre-Arranged 10b5-1 Plan: The sale of 6,000 shares was conducted pursuant to a Rule 10b5-1 trading plan adopted on November 26, 2025.
- Remaining Position: Following these transactions, Mr. Cozadd directly holds 351,875 Ordinary Shares.
- Significance: Low. The open-market disposition represents less than 2% of his total equity holdings and was executed through a pre-established 10b5-1 plan.
Get Real-Time Alerts
Join our community to receive instant notifications when high-significance filings are published
Important Disclaimer
This content is drawn from public SEC filings and may contain errors. It is for informational purposes only and is not investment, legal, or tax advice.
Nothing here is a recommendation to buy, sell, or hold any security. Do your own due diligence.